Lung Cancer: Lung Cancer: Genetics |

Personalized Therapy With Genetic Susceptibility to Advanced Non-small Cell Lung Cancer FREE TO VIEW

Yinlou Yang, MD
Author and Funding Information

Affiliated Yuebei People's Hospital, Medical College of Shantou University, Shaoguan City, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A280. doi:10.1016/j.chest.2016.02.292
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer: Genetics

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Advanced non-small cell lung cancer (NSCLC) therapy is individualized for each patient based on the molecular characterization under the guidance of evidence-based medicine, do not violate the basic principles of standardization of treatment, a reasonable first-line, second-line or third-line chemotherapy, biological targeting treatment. The impact of chemotherapy-related molecular markers include the tumor excision repair cross-complementation group 1 (ERCC1) the expression level of platinum-based drugs, ribonucleotide reductase regulatory factor 1 (RRM1) expression levels with gemcitabine, thymidylate synthase (TS) expression levels with the efficacy of the drug. impact of the biological efficacy of targeted drug-related molecular markers include the epidermal growth factor receptor (EGFR) mutation status, K- ras mutation status and ALK fusion gene in NSCLC signaling pathway as a target of drug efficacy

METHODS: according to the principles of the multidisciplinary treatment of NSCLC in 2011 NCCN guidelines were standard treatment, the need for chemotherapy, molecular targeted therapy, 20 cases of individualized treatment advanced NSCLC patients, the use of biological markers to guide treatment, based on molecular markers treatment roadmap, complete with genetic testing based on susceptibility testing NCSLC optimize individual therapy as a study group. Another susceptibility gene testing randomly selected 20 patients did not undergo conventional chemotherapy in patients with advanced NSCLC as a control group, observed susceptibility gene testing advanced disease remission rate in patients with NSCLC optimize individual treatment, objection response rate, disease progression (PFS), quality of life score were observed.

RESULTS: objection response rate, without disease progression (PFS), quality of life ratings of Study group and the control group of advanced NSCLC patients were 92% versus 76% (p <0.05), 14.2 versus 9.9month (p <0.05), 37.2 versus 28.2 (p <0.05), showed that the use of biological markers to guide treatment, based on molecular markers by advanced NCSLC individualized treatment roadmap, individualized treatment of patients with advanced disease NCSLC remission rate, progression-free (PFS), survival Quality scores were significantly higher than advanced NCSLC did not undergo genetic testing for susceptibility of conventional chemotherapy control group

CONCLUSIONS: Based on molecular biological markers, can guide individual treatment of clinically advanced NCSLC


DISCLOSURE: The following authors have nothing to disclose: Yinlou Yang





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543